What Does Amarin's ANCHOR Mean for Investors?


Amarin gained FDA approval for its drug Vascepa last summer and this lipid-lowering compound is already available to patients in the U.S. However, the company announced today that it has submitted an sNDA, or supplemental new drug application, to expand the drug's approval to a wider patient population. In this video, Fool health-care analyst Max Macaluso explains what this application means, why wider approval could potentially be a boon for this biotech, and long-term risks that investors can't ignore.

Can Amarin Beat the Odds?

Small biotech companies usually crash and burn when it comes to launching drugs -- but can Amarin prove the doubters wrong with its new lipid-lowering drug? In our new premium research report, The Motley Fool's top biotech analyst offers an in-depth look at this drugmaker's upcoming opportunities, along with reasons to buy and sell this stock today. To find out more -- and receive a full year of free bonus updates as news develops -- simply click here now to claim your copy.

The article What Does Amarin's ANCHOR Mean for Investors? originally appeared on Fool.com.

Max Macaluso, Ph.D. has no position in any stocks mentioned, and neither does The Motley Fool. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.